Wang Evelyn A, Chan Sanny K
Dept. of Pediatrics, Div. of Allergy and Immunology, National Jewish Health, Denver, CO, 80206, USA.
Dept. of Biomedical Research, National Jewish Health, Denver, CO, 80206, USA.
Curr Allergy Asthma Rep. 2020 Jun 6;20(8):31. doi: 10.1007/s11882-020-00929-1.
Both adults and children are frequently affected by symptoms of itchy urticarial lesions that cause considerable distress and impact nearly all their daily activities. A comprehensive history is critical to identify the etiology in patients who have chronic spontaneous urticaria (CSU) (those with symptoms for > 6 weeks) and is more important than extensive laboratory serum tests. Unfortunately, most of the current treatment guidelines have been based on data from adult studies since there is rare data on children. These treatment algorithms have been subsequently used to extrapolate treatments for children.
Current treatment regiments do not achieve complete success in all patients, neither adults nor children. As the pathophysiology of chronic urticaria slowly becomes defined, novel therapies are being tested which target these individual molecular pathways to treat those that continue to experience symptoms. Future studies are required to establish the natural history, risks/benefits and efficacy of current medications, and biologics used to treat CSU in children.
成人和儿童都经常受到瘙痒性荨麻疹皮损症状的影响，这些症状会造成相当大的痛苦，并几乎影响到他们所有的日常活动。全面的病史对于确定慢性自发性荨麻疹（CSU）（症状持续超过6周）患者的病因至关重要，并且比广泛的实验室血清检测更重要。不幸的是，由于儿童数据稀少，目前大多数治疗指南都是基于成人研究的数据。这些治疗算法随后被用于推断儿童的治疗方法。
目前的治疗方案在所有患者（无论是成人还是儿童）中都没有完全成功。随着慢性荨麻疹的病理生理学逐渐明确，正在测试针对这些个体分子途径的新疗法，以治疗那些仍有症状的患者。未来需要开展研究，以确定用于治疗儿童CSU的现有药物和生物制剂的自然病程、风险/益处及疗效。
